CION Ameerpet
Yes — CA-125 can sit inside the normal range in a woman who does have ovarian cancer. It happens often enough that no experienced specialist uses this blood test to rule the disease out. A normal result lowers the probability; it does not close the question. Here is why it happens, and what should happen next.
Yes. You are probably here because a result came back inside the normal range and the symptoms did not go away — or because you read about someone diagnosed after a reassuring blood test. Searching normal CA125 but ovarian cancer is a reasonable thing to do, and the honest answer is that this happens, regularly, and it is well described in the medical literature.
The reason lies in what the test measures. CA-125 is a protein shed by tissues derived from the coelomic epithelium — the same embryological lining that covers the ovaries and the inside of the abdomen. It enters the bloodstream in quantity when there is a large volume of tumour, or when the peritoneum is irritated. A small tumour, still confined to one ovary, may simply not release enough of it to move the number. And several ovarian tumour types barely make the protein at all.
So the practical rule that specialists work to is this: a normal CA-125 lowers the probability of ovarian cancer, but it does not close the question, and it never overrides a scan or a persistent symptom pattern. If you want the other half of the picture — what a raised number means, and why it is so often benign — read how to read a CA-125 result properly.
Most laboratories call anything under 35 U/mL normal. That cut-off came from the spread of values in healthy women, not from a study of who turns out to have cancer. It was chosen to keep false alarms down, which means some cancers fall below it.
The stage at which an early answer would change the most is exactly the stage at which CA-125 performs worst. Sensitivity climbs as disease advances — useful for monitoring, unhelpful for catching things early.
CA-125 was developed to follow a known cancer, not to find an unknown one. Using it as a general check produces false reassurance in some women and unnecessary alarm in many more.
CA-125 rises above the usual 35 U/mL threshold in roughly 80% of epithelial ovarian cancers taken as a whole — but in only about half of women with stage I disease, which is precisely the group in whom an early answer would matter most. Sensitivity is lower again in mucinous and clear cell carcinomas, while germ cell and sex-cord stromal tumours commonly raise entirely different markers and leave CA-125 untouched. This is why national guidance treats a normal CA-125 in a woman with persistent symptoms as a reason to keep looking, not a reason to stop. Source: Jacobs I & Bast RC, Human Reproduction (1989); NICE CG122, Ovarian cancer: recognition and initial management; NCCN Ovarian Cancer guidelines.
A false negative is not a laboratory error. In almost every case the number is accurate — it is simply answering a narrower question than the one you are asking. These are the situations in which a correct CA-125 result is still a misleading one.
CA-125 enters the bloodstream in proportion to how much tumour there is and how much the peritoneal lining is involved. A cancer still confined to one ovary has a small surface area, no peritoneal spread and no ascites, so there is little to detect. Around half of stage I epithelial ovarian cancers sit inside the normal range for this reason alone.
This is the uncomfortable part of the test's behaviour. Its sensitivity is worst exactly where detection would help most, and best in advanced disease that is already causing obvious symptoms. It is a good marker for tracking a cancer you already know about, and a poor one for deciding whether a cancer exists.
The protein CA-125 is expressed strongly by high-grade serous tumours, which are the commonest ovarian cancers and the ones the test was effectively designed around. Mucinous carcinomas frequently produce normal or only mildly raised values, and clear cell carcinomas are variable, particularly at an early stage.
If your scan shows a mass with mucinous or clear cell features, the blood marker deserves much less weight in the discussion than the imaging does. Other markers may be more informative in these subtypes, and the choice of which to send is made after the scan, not before it.
Not every ovarian cancer is epithelial. Germ cell tumours, which are the type most often seen in teenagers and women in their twenties, usually leave CA-125 completely normal — they are reflected instead by AFP, beta-hCG and LDH. Sex-cord stromal tumours such as granulosa cell tumours are typically tracked by inhibin B and anti-Müllerian hormone.
This matters most for young women. A 22-year-old with an ovarian mass and a normal CA-125 has been given almost no information at all, because the wrong panel was sent. Age and the appearance of the mass on ultrasound should decide which markers are requested.
Borderline ovarian tumours — also called tumours of low malignant potential — behave less aggressively than invasive cancer, and their markers reflect that. CA-125 is frequently normal or only marginally raised, even when the tumour is large enough to be causing pressure symptoms.
These tumours are identified from how the mass looks on a transvaginal scan and, definitively, from the tissue once it is removed. They are one of the clearest illustrations of why the scan leads and the blood test follows.
Healthy women vary widely in their baseline CA-125. If yours has always run at 6 or 8 U/mL, a result of 30 is a three- to fivefold rise — and it will still be reported as normal, because 30 is under 35. A single value read against a population cut-off throws that information away.
This is why a trend is far more informative than a snapshot, and why a repeat test some weeks later can occasionally reveal something a single result hid. It is also why the number should always be read next to your scan and your symptoms rather than on its own.
CA-125 earns its place after a diagnosis, where a falling value during treatment and a stable value afterwards give genuinely useful information about how the disease is behaving. Used that way, each woman is compared against her own previous results rather than against a population threshold, and the test performs well.
Used the other way round — as a check to see whether something is wrong — it is being asked to do a job it was not designed for. Large screening trials have not shown that CA-125 testing reduces deaths from ovarian cancer, which is why it is not offered as a screening test to women without symptoms.
The same blood test behaves very differently depending on what kind of tumour is present. This is typical behaviour rather than a rule, but it explains most normal results in women who do turn out to have ovarian cancer.
| Tumour type | How CA-125 usually behaves | Markers that may be more informative |
|---|---|---|
| High-grade serous carcinoma | Raised in the large majority, often markedly, and rises further once there is peritoneal spread or ascites. | CA-125 is the appropriate marker here; HE4 and the ROMA score add precision where a mass is already known. |
| Low-grade serous carcinoma | Often raised, but usually far less dramatically than high-grade disease. | CA-125 read as a trend across serial tests, alongside imaging. |
| Mucinous carcinoma | Frequently normal or only mildly raised. CA-125 sensitivity is at its poorest in this subtype. | CEA and CA 19-9 are sometimes more useful; the scan leads the assessment. |
| Clear cell and endometrioid carcinoma | Variable, and may be normal at an early stage. | Imaging with HE4 and the ROMA score; a history of endometriosis is relevant context. |
| Germ cell tumours (typically younger women) | Usually normal — these tumours do not characteristically express CA-125. | AFP, beta-hCG and LDH, which are the markers to send in a young woman with an ovarian mass. |
| Sex-cord stromal tumours, including granulosa cell | Commonly normal. | Inhibin B and anti-Müllerian hormone. |
| Borderline (low malignant potential) tumours | Often normal or only marginally raised despite a sizeable mass. | The appearance of the mass on transvaginal ultrasound, and specialist review of the images. |
*Markers are chosen after imaging, not before it, because the scan is what indicates which panel is worth sending. If you are unsure which second marker applies to you, read HE4 and the ROMA score explained.
None of these means you have cancer — the overwhelming majority of women with these symptoms and a normal marker do not. Each is a reason to have imaging arranged rather than to be reassured by a blood test alone.
New bloating that does not settle overnight or after your bowels open, present on most days for several weeks, warrants a pelvic ultrasound whatever the blood marker showed.
Early satiety with a dropping appetite, alongside bloating, is a more concerning combination than either symptom alone and should not be filed under indigestion.
Not a feeling of tightness but a real change — waistbands that no longer fasten, or visible swelling. This needs prompt imaging, because free fluid can be present with a normal marker.
Pain that has changed character, become constant, or appeared for the first time after the periods stopped, deserves an examination and a scan rather than a repeat blood test.
New, persistent abdominal or pelvic symptoms after the menopause carry more weight than the same symptoms at 30, because the benign hormonal explanations no longer apply.
A pathogenic BRCA1 or BRCA2 variant, Lynch syndrome, or several close relatives with ovarian, breast, bowel or endometrial cancer lowers the threshold for imaging considerably.
If you carry a BRCA1 or BRCA2 variant, be clear about one thing: CA-125 testing and ultrasound surveillance have never been shown to reduce deaths from ovarian cancer, in carriers or in anyone else. There is no effective screening test for this disease. A normal surveillance result is not protection, and new symptoms should be acted on when they appear rather than saved for the next scheduled test.
A 45-minute consultation, a clinical examination and, where the history warrants it, a pelvic ultrasound — not a repeat of the blood test that already came back normal. Most women leave reassured, this time for a reason that holds.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If the assessment is genuinely reassuring we will say so plainly — and explain what made it reassuring, rather than pointing at one number. See how ovarian cancer is treated at CION.
None of this makes the test useless, and it is worth being as precise about what a normal result does mean as about what it does not. In a woman with no symptoms, a normal examination and a normal scan, a normal CA-125 is one more piece of evidence pointing the same way, and the combined picture is genuinely reassuring. Most women reading this page are in exactly that position.
A normal CA-125 also makes advanced epithelial ovarian cancer considerably less likely, because widespread peritoneal disease almost always pushes the number up. That is a real and useful piece of information. What it cannot do is exclude early disease, or any of the subtypes that do not express the protein.
The mistake is not ordering the test. The mistake is letting one normal number end a conversation that the symptoms have not ended. A blood marker is a supporting witness; the scan is the evidence. When the two disagree, the scan wins.
Advanced epithelial ovarian cancer with peritoneal spread. Extensive disease of that kind rarely leaves CA-125 in the normal range, so a normal value carries real weight against it — particularly when the examination and the scan agree.
Early-stage disease, mucinous and clear cell carcinoma, germ cell and sex-cord stromal tumours, and borderline tumours. It also cannot tell you whether your own value has risen substantially from a much lower personal baseline.
A sensible next step is rarely another blood test. It is usually a proper look at the ovaries, and a conversation long enough to establish the pattern of what you are experiencing.
How long the symptoms have been there, how many days a month, whether they settle overnight or after your bowels open, and whether they track your cycle. Frequency and persistence are what a specialist reads, and a two-week diary answers the question far better than memory does. This is the single most useful thing you can bring.
If the ovaries have not been looked at, a transvaginal and transabdominal ultrasound is the appropriate next step. It is painless, radiation-free and looks directly at the organ in question. Repeating a normal CA-125 in the absence of a scan usually just delays the answer by a few weeks.
In a woman under about 30 with an ovarian mass, CA-125 alone is the wrong panel. AFP, beta-hCG, LDH and inhibin B are what reflect germ cell and sex-cord stromal tumours. If you are young and were sent home on a normal CA-125 without a scan, that deserves revisiting.
Where imaging shows an ovarian mass, a second marker read alongside CA-125 and your menopausal status refines the risk assessment better than either marker alone. It is used to decide how urgently and to whom you should be referred — see HE4 and the ROMA score for how the calculation works.
A normal result three months ago is not an answer today. If the symptoms are still there, or have progressed, go back and say so explicitly — that the pattern has continued despite a normal marker. That sentence changes how the consultation proceeds, and it is entirely reasonable to ask for a second opinion at that point.
If a diagnosis does follow, you are not starting from nothing — see what ovarian cancer treatment involves, or read the complete ovarian cancer guide for the full picture.
A normal blood test is one of the easiest ways for a real problem to be closed down early, because it gives everyone in the room something reassuring to point at. Reading it correctly takes the one thing a short appointment cannot provide: enough time to establish the symptom pattern, the family history and the menopausal context that decide how much weight the number should carry.
Your first consultation at CION is free and runs to about 45 minutes. We would rather arrange the scan that answers the question than repeat the test that already did not. Equally, we will not order a panel of markers to look thorough — where the history and the examination are genuinely reassuring, we say so plainly and explain what made them reassuring. Cases that raise a question go to a tumour board rather than being decided by one doctor alone.
If an ovarian cancer is found, medical oncology is delivered in-house at CION: chemotherapy and maintenance therapy across 35+ centres in Telangana and Andhra Pradesh, together with genetic counselling and BRCA and HRD testing where the diagnosis or family history warrants it, plus nutrition support and long-term follow-up. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there — we say that upfront rather than leaving you to discover it later.
Free, unhurried and with a specialist. Long enough to take the history that decides what a normal marker is actually worth in your case.
Cases that raise a question are reviewed by a multidisciplinary group — medical oncology, imaging and pathology — rather than by a single clinician.
Decisions for healing, not billing. We arrange the investigation that answers the question, and leave out the ones that only add cost and anxiety.
Chemotherapy, maintenance therapy and follow-up can be delivered near where you live rather than requiring repeat trips to a single city hospital.
Yes. It is well recognised and it is one of the main reasons CA-125 is never used on its own to rule ovarian cancer out. The marker is raised in roughly 80% of epithelial ovarian cancers overall, but in only about half of women with stage I disease, and it is frequently normal in mucinous, clear cell, germ cell, sex-cord stromal and borderline tumours. A normal result makes advanced epithelial disease less likely, which is genuinely useful, but it cannot exclude early or non-serous cancer. If your symptoms are persisting, the appropriate next step is a pelvic ultrasound rather than a repeat of the blood test.
It depends almost entirely on the stage and the subtype rather than on the laboratory. Across all epithelial ovarian cancers, around one in five has a CA-125 within the normal range. In stage I disease that proportion rises to roughly half. In mucinous carcinoma, in germ cell tumours and in sex-cord stromal tumours, a normal CA-125 is common rather than exceptional, because those tumours do not characteristically produce the protein the test measures. So a false negative is not a rare event, and it is not evidence that anything went wrong with the sample — the test simply answers a narrower question than most people assume it does.
It is normal against the laboratory's reference range, which is usually anything under 35 U/mL. Whether it is normal for you is a different question. Healthy women vary widely in their baseline: if yours has always been around 6, a value of 20 represents a threefold rise while still being reported as normal. A single result read against a population cut-off cannot show that. This is why a trend across two or more tests is more informative than one snapshot, and why the number should be read next to your scan, your age and your symptoms rather than on its own. If you have a previous CA-125 result, bring it to the appointment.
Germ cell tumours, which are the type most often seen in teenagers and young women, usually leave CA-125 untouched and are reflected instead by AFP, beta-hCG and LDH. Sex-cord stromal tumours such as granulosa cell tumours are typically tracked by inhibin B and anti-Müllerian hormone. Mucinous carcinomas frequently produce a normal or only mildly raised value, and borderline tumours often do the same. Clear cell and endometrioid carcinomas are variable, particularly early on. High-grade serous carcinoma, the commonest type, is the one that reliably raises CA-125 — which is effectively the tumour the test was built around.
If your ovaries have not been imaged and your symptoms are persisting, a scan. A transvaginal and transabdominal ultrasound looks directly at the ovaries and the abdomen, is painless and radiation-free, and in most women identifies a benign explanation or nothing abnormal at all. Repeating a normal blood marker without imaging tends to postpone the answer rather than provide it. A repeat CA-125 does have a role where a scan has already been done and a trend is being followed, or where a first result was borderline and taken during a period or an episode of pelvic inflammation. Your doctor should be able to explain which of those situations applies to you.
No, and this is worth being blunt about. There is no ovarian cancer screening test that has been shown to reduce deaths from the disease — not CA-125, not transvaginal ultrasound, not the two combined, and that is true for BRCA1 and BRCA2 carriers as much as for anyone else. Surveillance may find some cancers, but it has not been shown to find them early enough to change the outcome. A normal surveillance result is therefore not protection. If you develop new persistent symptoms between tests, act on them then rather than waiting for the next appointment, and discuss risk-reducing options and genetic counselling with a specialist who manages high-risk women.
The first consultation is free and runs to about 45 minutes. CION delivers medical oncology for ovarian cancer in-house, covering chemotherapy and maintenance therapy across more than 35 centres in Telangana and Andhra Pradesh, together with genetic counselling, BRCA and HRD testing, nutrition support and long-term follow-up. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there — we say so upfront rather than leaving it to be discovered later. Every case that raises a question is reviewed at a tumour board rather than decided by one doctor alone.